Drugs / Varicella vaccine

Trials 15 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2/31 trial
Phase 2/3 NCT00926419 Jun → Nov 2009 chickenpox, hepatitis A virus infection University of Sao Paulo General Hospital Unknown No outcome recorded
Phase 35 trials
Phase 3 NCT07473427 Jun → Aug 2026 overdue chickenpox Sinovac (Dalian) Vaccine Technology Co., Ltd. Not yet recruiting No outcome recorded
Phase 3 NCT06314724 Feb → Sep 2024 chickenpox Sinovac (Dalian) Vaccine Technology Co., Ltd. Completed No outcome recorded
Phase 3 NCT03537508 Apr 2018 → Sep 2023 Sanofi Pasteur, a Sanofi Company Completed No outcome recorded
Phase 3 NCT00483470 Jun 2007 → May 2008 hepatitis A virus infection Sanofi Pasteur, a Sanofi Company Completed No outcome recorded
Phase 3 NCT00213304 Jun 1999 → Dec 2016 disease related to solid organ transplantation The Hospital for Sick Children Completed No outcome recorded
Phase 49 trials
Phase 4 NCT06891872 May → Dec 2025 overdue chickenpox, primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection Sinovac (Dalian) Vaccine Technology Co., Ltd. Not yet recruiting No outcome recorded
Phase 4 NCT06994052 Sep → Nov 2024 chickenpox Sinovac (Dalian) Vaccine Technology Co., Ltd. Completed No outcome recorded
Phase 4 NCT06987942 Sep → Nov 2024 chickenpox Sinovac (Dalian) Vaccine Technology Co., Ltd. Completed No outcome recorded
Phase 4 NCT05952505 Aug → Dec 2023 COVID-19, chickenpox, measles, mumps infectious disease +1 Shanghai Municipal Center for Disease Control and Prevention Unknown No outcome recorded
Phase 4 NCT03330171 Apr 2017 → Feb 2019 chickenpox, hepatitis A virus infection, measles University of Witwatersrand, South Africa Unknown No outcome recorded
Phase 4 NCT02173899 Jun → Aug 2014 chickenpox Changchun Keygen Biological Products Co., Ltd. Completed No outcome recorded
Phase 4 NCT01866566 Jun 2013 → Jan 2014 chickenpox Beijing Center for Disease Control and Prevention Unknown No outcome recorded
Phase 4 NCT01830283 Apr → Jun 2013 chickenpox Beijing Center for Disease Control and Prevention Unknown No outcome recorded
Phase 4 NCT02146469 Dec 2012 → Jun 2014 chickenpox Shanghai Municipal Center for Disease Control and Prevention Unknown No outcome recorded
Also used as a comparator or background therapy in 7 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/22 trials
Phase 1/2 NCT04072497 Comparator Nov 2018 → Apr 2020 herpes zoster Shanghai Institute Of Biological Products Completed No outcome recorded
Phase 1/2 NCT00322049 Comparator Feb 2004 → Jun 2009 dengue disease U.S. Army Medical Research and Development Command Completed No outcome recorded
Phase 21 trial
Phase 2 NCT01064141 Comparator Jan 2010 → Sep 2012 Dengue hemorrhagic fever Sanofi Completed No outcome recorded
Phase 31 trial
Phase 3 NCT01190228 Comparator Aug → Oct 2010 Japanese encephalitis, chickenpox Sanofi Pasteur, a Sanofi Company Completed No outcome recorded
Phase 42 trials
Phase 4 NCT02026089 Comparator Dec 2021 → Jun 2022 chickenpox University of Colorado, Denver Withdrawn No outcome recorded
Phase 4 NCT01693380 Background May → Jun 2009 influenza Butantan Institute Completed No outcome recorded
Phase not applicable1 trial
NCT06313762 Background Jan 2022 → Jan 2024 Jordi Gol Institute for Primary Care Research Completed No outcome recorded

Evidence & citations 9 cited values

Every value below carries the sentence it was read from. 23 sources stand behind the page.

FieldValueCited text
Known as Varicella vaccine “of Meningococcal C conjugate vaccine, and one dose (0.5ml), one month later, of varicella vaccine, IM administered.” NCT01693380
19

“Subjects will be coadministered with inactivated SARS-CoV-2 vaccine and varicella vaccine.” NCT05952505

“Give 2 doses varicella vaccine (a single 0.5 mL) and get blood samples at 0,1.5,4.5 month” NCT01866566

“1 dose Varicella vaccine and 1 dose MMR given at the same time” NCT02146469

“Give the second varicella vaccine (a single 0.5 ml)” NCT02173899

Varicella VaccineNCT06891872

NCT03330171

NCT06314724

NCT00926419

NCT04072497

NCT00322049

NCT06987942

NCT03537508

NCT01190228

NCT00213304

NCT06994052

NCT07473427

NCT06313762

NCT01830283

NCT02026089

Known as Avaxim “Healthy anti-hepatitis A virus seronegative subjects aged 13 to 19 yr were randomized in three equal groups to receive two doses of Avaxim™, Epaxal®, or Havrix®, 6 to 12 months apart.” PMID 26770041 Dec 2015
Known as AVAXIM 80U “AVAXIM® 80U” NCT01064141
2

NCT01064141

NCT00483470

Known as AVAXIM 80U Pediatric vaccine AVAXIM 80U Pediatric vaccineNCT00483470
Known as OKAVAX OKAVAX®” NCT01064141
1

NCT01064141

Known as varicella live attenuated vaccine “The goal of this clinical trial is to evaluate the immunogenicity of simultaneous administration of varicella live attenuated vaccine (varicella vaccine hereafter) and...” NCT06987942
Known as VARIVAX “varicella vaccine (VARIVAX)” NCT00213304
Modality Vaccine “Safety and Immunogenicity of Live Attenuated Oka/Merck Varicella Vaccine in Children Listed to Undergo Solid Organ Transplantation” NCT00213304
Route Subcutaneous “0.5 mL (single dose), SubcutaneousNCT01190228